Lake Street analyst Brooks O'Neil says shares of Tandem Diabetes fell sharply last week following the release of positive results from two "critical" studies of the t:slim X2 Insulin Pump with Control-IQ Technology. "This reminds us of the reaction of the stock following the release of exceptional Q1 results delivered by Tandem on April 30, 2019," O'Neil tells investors in a research note. While both industry leaders and upstarts are touting "next generation" platforms, only Tandem has conducted a pivotal trial to prove its next gen system's capabilities, O'Neil adds. He reiterates a Buy rating on the shares with a $100 price target.